A first wave of molecular glue and heterobifunctional degraders mostly focused on well-validated targets. A second surge is now pushing into more novel target space. “We're on the cusp of a ...

Two decades of continuous efforts to develop heterobifunctional degraders have brought targeted protein degradation to an exciting and promising era of next-generation medicines. TPD by PROteolysis ...

The histone acetyltransferase KAT2A, and its paralog KAT2B have been identified as key drivers of tumor cell plasticity in small-cell lung cancer (SCLC). Researchers from Auron Therapeutics Inc. aimed ...

However, due to its strong cardiotoxicity, bufalin has limited translational potential. A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to ...

The T-cell malignancies market is driven by the rising incidence of these cancers, advancements in treatment options, and ...

The posters presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell ...

Semiconductors have a valence band that is filled with electrons and an empty conduction band separated by a band gap (also called energy gap). For an electron to be excited into the conduction ...

Researchers from Mariana Oncology Inc. reported preclinical data on MC-339, a DLL3-targeting macrocyclic peptide in several tumor models. Delta-like ligand 3 (DLL3) is overexpressed on the cell ...

Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today ...